文献速递肾癌与肾肿瘤

纳武利尤单抗治疗晚期肾细胞癌患者中超越进展的治疗:CheckMate 025研究

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.
PubMed 文献 · Eur Urol · 2017-04-12

该研究为CheckMate 025三期试验中亚组分析,评估纳武利尤单抗治疗晚期肾细胞癌患者超越RECIST进展后继续治疗的疗效。406例接受纳武利尤单抗治疗的患者中316例(78%)出现RECIST进展,其中48%为超越进展后继续治疗(TBP),52%未超越进展后治疗(NTBP)。TBP患者中13%出现≥30%肿瘤负荷减少,且TBP患者进展后治疗相关不良事件发生率(59%)低于进展前(71%)。

要点

  • 晚期肾细胞癌RECIST进展后继续纳武利尤单抗治疗,部分患者出现肿瘤缩小。
  • TBP患者进展后治疗相关不良事件发生率为59%,低于进展前的71%。
  • 临床判断在更换治疗时仍至关重要。

核心结论

  • 部分晚期肾细胞癌患者经纳武利尤单抗治疗后出现RECIST进展,但进展后仍可观察到肿瘤缩小,且安全性可接受。

研究设计与样本

  • CheckMate 025三期研究中亚组分析,纳入接受纳武利尤单抗治疗的晚期肾细胞癌患者406例。
  • TBP定义为首次RECIST进展后继续治疗≥4周且耐受治疗并显示研究者评估的临床获益;NTBP定义为进展后治疗0周至<4周。

主要发现

  • 406例接受纳武利尤单抗治疗患者中316例(78%)出现RECIST进展,其中48%为TBP,52%为NTBP。
  • TBP前客观缓解率(95%CI)在TBP患者为20%(14-28),在NTBP患者为14%(9-21)。
  • 首次进展时TBP与NTBP患者的临床特征差异包括:TBP患者Karnofsky体能状态更好、Karnofsky体能状态恶化更少、至缓解时间更短、新发骨病灶发生率更低、生活质量改善。
  • TBP患者进展后有13%(20/153)出现≥30%肿瘤负荷减少,包括进展前和进展后均有肿瘤测量的患者(n=142)以及TBP前最佳疗效为完全/部分缓解(28%,8/29)、疾病稳定(6%,3/47)和疾病进展(14%,9/66)的患者。
  • TBP患者治疗相关不良事件发生率进展后为59%,进展前为71%。

临床怎么用

  • 原文结论指出,临床判断在更换治疗时仍至关重要。

局限性

  • 局限性包括分析的非随机性质可能带来的偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Response patterns to nivolumab differ from those seen with other approved targeted therapies. OBJECTIVE: To investigate the efficacy of nivolumab in previously treated patients with advanced renal cell carcinoma who were treated beyond (Response Evaluation Criteria In Solid Tumors) RECIST progression. DESIGN, SETTING, AND PARTICIPANTS: This was a subgroup analysis of patients treated with nivolumab in the phase 3 CheckMate 025 study. Patients continuing to tolerate therapy and exhibiting investigator-assessed clinical benefit were eligible to be treated beyond RECIST progression (TBP) and received therapy for ≥4 wk after first progression; patients not treated beyond RECIST progression (NTBP) received 0 wk to <4 wk of therapy after progression. INTERVENTIONS: Nivolumab 3mg/kg intravenously every 2 wk. RESULTS AND LIMITATIONS: Of 406 nivolumab-treated patients, 316 (78%) progressed by RECIST criteria. Of those who progressed, 48% were TBP, 52% were NTBP. Before being TBP, objective response rate (95% confidence interval) was 20% (14-28) and 14% (9-21) in patients TBP and NTBP, respectively. Differences in clinical characteristics assessed at first progression between patients TBP versus NTBP included better Karnofsky performance status, less deterioration in Karnofsky performance status, shorter time to response, lower incidence of new bone lesions, and improved quality of life. Postprogression, 13% of all patients TBP (20/153) had ≥30% tumor burden reduction including patients with preprogression and postprogression tumor measurements (n=142) and complete/partial response (28%, 8/29), stable disease (6%, 3/47), and progressive disease (14%, 9/66) as their best response before being TBP. Incidence of treatment-related adverse events in patients TBP was lower after (59%) versus before (71%) progression. Limitations included potential bias from the nonrandomized nature of the analysis. CONCLUSIONS: A subset of patients with advanced renal cell carcinoma and RECIST progression experienced tumor reduction postprogression with nivolumab, and had an acceptable safety profile. Clinical judgment remains essential when switching therapy. ClinicalTrials.gov Identifier: NCT01668784. PATIENT SUMMARY: A subset of patients with advanced renal cell carcinoma and disease progression may continue to benefit from nivolumab treatment beyond progression as evidenced by tumor reduction postprogression and an acceptable safety profile.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Escudier B, Motzer RJ, Sharma P, et al. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. Eur Urol. 2017. PMID: 28410865. doi:10.1016/j.eururo.2017.03.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。